Virtual Screening for Lead Molecules in Aegle Marmelos (L.) Correa. on Mutated Ras Proteins


Nisha Nisha Bhavan Chandran1 and Rogimon Plammoottil Thomas2*

1Department of Botany, Assumption College (Autonomous), Changanassery, Kerala, India.

2Department of Botany, CMS College Kottayam (Autonomous), Kerala, India.

Corresponding Author Email: rogimon@cmscollege.ac.in

Download this article as: 

ABSTRACT:

India's rich biodiversity is complemented by its vast knowledge of medicinal plants and traditional practices, with plant-based compounds having been harnessed as therapeutic agents for centuries. Cancer, a leading cause of global mortality, is fundamentally driven by DNA abnormalities that disrupt the function of key metabolic proteins. Ras proteins show a vital role in cell signalling, regulating cell proliferation and apoptosis, but mutations in these proteins may results in uncontrolled cell growth. This study investigated the anticancer potential of phytochemicals against mutated H-RAS, N-RAS, and K-RAS (RAS proteins) using molecular docking analysis. Aegle marmelos, rich in over a hundred phytochemicals with reported anticancer properties, was the source of 89 molecules screened as ligands. Seventy-eight molecules exhibited strong binding affinity (∆Gbind ≤ -5 kcal/mol) for H-Ras, 74 for K-Ras, and 77 for N-Ras, with α-amyrin and lupeol emerging as top leads for H-Ras, betulinic acid, β-amyrin, and lupeol for K-Ras, and βand α-amyrins for N-Ras. α-Amyrin emerged as a promising lead molecule against mutated Ras proteins, showing strong potential against H-Ras and N-Ras, and comparable efficacy to top leads against K-Ras. To overcome the challenges observed in drug likeness prediction connected with alpha amyrin, nano emulsion formulations strategies can improve its bioavailability and efficacy. Further validation of the lead molecules' anticancer efficacy requires comprehensive preclinical and clinical studies to confirm their biological activity.

KEYWORDS:

Aegle marmelos; Anticancer; Auto Dock; Molecular docking; Phytochemicals; Ras proteins

Introduction

Cancer is a severe metabolic disorder recognized by abnormal proliferation of cells that spread all over the body and affect the normal functions of the body systems including  nervous, circulatory, endocrine, and digestive systems.1 The World Health Organization data proclaimed that cancer is one of the major mortality which killed around ten million people in the year, 2020 (https://www.who.int/news-room/fact-sheets/detail/cancer) and the number of cancer patients will be increased to 21 million by 2030.2 Cancer is caused by several factors such as gene mutations, disruption of the immune system, and the effect of various carcinogens.1 The consequences of this diseased condition is driven by both genetic and epigenetic changes is the disruption of  signaling pathways of cells that controls mitosis, growth, and death.3 Consequently, this interruption leads to abnormal proliferation of cells as a result of the inhibition of the normal events of the cell cycle such as cell cycle arrest and programmed cell death.4

Ras genes encode for Ras proteins or GTPases, function as molecular switches that regulate cellular signalling pathways controlling cell differentiation, proliferation, and programmed cell death. Ras proteins become oncogenes when mutated and have a crucial role in human cancer which has inspired multiple attempts to find RAS inhibitors.5Mutant RAS genes fuel some of the deadliest cancers, including pancreatic, colorectal, and lung cancers, by sending non-stop signals that drive tumor growth and cell proliferation.6 The oncogenic mutations on the H-Ras, K-Ras, or N-Ras genes observed in most human tumors alter the normal functioning of those signaling pathways there by resulting in the development of tumours.7 Ras is a protooncogene that becomes an oncogene because of a single base change that results in an alteration in a single amino acid in the encoded protein. The major Ras mutation is the change of the amino acid at position 12 in H-Ras and K-Ras and at position 61 in and N-Ras.8,9 Only these few, very specific mutations can make a Ras proto-oncogene to an oncogene. These few changes in the amino acid residues are directly involved in the binding and splitting of the GTP.7 Ras mutations are found in around 19% of cancer patients and are often linked to unfavorable prognoses. Despite extensive research, K-Ras has remained a difficult target to tackle, largely due to its molecular structure that resists small-molecule binding. 10 Despite the high similarity between the protein products of the three Ras genes, K-Ras mutations are significantly more prevalent in cancer and RASopathies, and the analysis reveals a correlation between RAS protein expression levels (KRAS > NRAS > HRAS) and mutation frequencies.11

Cancer treatment comprises surgery, chemotherapy, immunotherapy, radiotherapy, photodynamic therapy, cancer vaccinations, and stem cell transformation as individually or in combination are effective but results in severe side effects such as limited bioavailability, toxicity, fast clearance, non-specificity, and restriction in metastasis. Current anticancer drugs often affect rapidly dividing normal cells, such as those in bone marrow and hair follicles, leading to significant side effects. The extensive investigation for the alternative treatment proposes the use of phytochemicals and their derived analogs will be the most possible option for the better and nontoxic cancer treatment.12

Aegle marmelos(L.) Correa., Bael, a member of the Rutaceae family, is widely recognized for its medicinal properties and has been utilized in traditional medicine systems.13 Previous investigations on the ethnopharmacological properties of the plant showed that the phytochemicals in the plant possess radio-protective,anti-neoplastic, chemoprotective, and chemopreventive effects, effective in cancer prevention and treatment.14 Present scenario, computer-aided drug discovery approaches significantly contribute to drug discovery experiments and their interpretation to expedite the entire process. The current study was designed to validate the anticancerous activity and to identify the lead phytochemicals against mutated Ras proteins in Aegle marmelos (L.) Correa, by in silico method.

Materials and Methods

Target molecule preparation

The three Ras proteins viz., H-Ras (1P2U), K-Ras (5UFE) and N-Ras (5UHV) were used for docking simulations. The three-dimensional structures of these proteins were sourced from RCSB Protein Data Bank. The oncogenic mutations reported by Pierotti et al., (2003)8 were done in the three dimensionalmolecular structures of these Ras proteins using Swiss PDB Viewer 4.0.115 (Fig. 1). The glycine residue at the 12 position of 1P2U and 5UFE was mutated to valine and aspartic acid respectively. In 5UHV, the glutamine residue at the 61 position was mutated to lysine. The mutated 1P2U, 5UFE and 5UHV were used as the receptor molecules for docking and the mutated residues were taken as active residues for the detection of active sites.

Figure 1: Mutated Ras Proteins  a) H-Ras, b) K-Ras, c) N-Ras 

 

Click here to view Figure

Preparation of ligand molecules 

The literature survey revealed that more than 100 phytochemicals have been so far reported from A. marmelos. Out of these, 89 molecules with molecular weights under 700 g/mol were selected for docking studies. The Canonical Simplified Molecular Input Line Entry Systems (Canonical SMILES) of the ligands were obtained from PubChem and 3D structures were created with CORINA.16The ligands chosen for docking are shown in Table 1.

Docking

Docking studies were performed using AutoDock 4.2, with the selected phytochemicals docked into the Ras protein’s binding site according to Morris et al., (2009).17 This tool leverages Monte Carlo Simulated Annealing and Lamarckian genetic algorithm for possible orientations of ligands at the Ras protein binding site. The active site residues of the proteins 1P2U, 5UFE and 5UHV were VAL12, ASP12 and LYS61 respectively. Grid dimensions of 60×60×60 points with 0.375Å spacing were specified for each protein. The active site was centered in the grid, with XYZ coordinates defined as: 1P2U – 24.721Å, 7.378Å, 38.718Å, 5UFE-10.117Å, 6.296Å, 3.87Å and 5UHV – 5.423Å, 24.44Å, 11.983Å respectively. All remaining parameters were maintained at their default values. After docking, the binding affinity and possible orientations of the ligand-protein complexes were analyzed and ranked by their binding energies using cluster analysis. Molecules with a binding energy ≤ -5 kcal/mol were considered potential hit compounds.16 The docked structures were visualized and images were created using PyMol visualization software.18

Table 1: The list of prioritized phytochemicals in Aegle marmelos 

Sl.

No.

Phytochemicals MolecularWeight

(g/mol)

Molecular

Formula

1 3,5-octadiene-2-one 124.18 C8H12O
2 3-Phenylacrylamide 147.17 C9H9NO
3 Acetoin 88.11 C4H8O2
4 Alloimperatorin 270.28 C16H14O4
5 Ascorbicacid 176.12 C6H8O6
6 Aurapten 298.4 C19H22O3
7 Betulinicacid 456.7 C30H48O3
8 Carvone 150.22 C10H14O
9 Carvylacetate 194.27 C12H18O2
10 Caryophylleneoxide 220.35 C15H24O
11 Cineole 154.25 C10H18O
12 Cis-carveol 152.23 C10H16O
13 Citral 152.23 C10H16O
14 Citronellal 154.25 C10H18O
15 Cuminaldehyde 148.2 C10H12O
16 Decursinol 246.26 C14H14O
17 Dictamine 199.2 C12H9NO2
18 Elemol 222.37 C15H26O
19 Emodin 270.24 C15H10O5
20 Eugenol 164.2 C10H12O2
21 Fagarine 229.23 C13H11NO3
22 Farnesol 222.37 C15H26O
23 Flavone 222.24 C15H10O2
24 Furoquinoline 169.18 C11H7NO
25 Geraniol 154.25 C10H18O
26 Haplopine 245.23 C13H11NO4
27 Limonene 136.23 C10H16
28 Linalool 154.25 C10H18O
29 Lupeol 426.7 C30H50O
30 Luvangetin 258.27 C15H14O4
31 Marmeline 335.44 C22H25NO2
32 Marmelosin 270.28 C16H14O4
33 Marmesin 246.26 C14H14O4
34 Marmesinin 408.4 C20H24O9
35 Marmin 332.4 C19H24O5
36 Methylcinnamate 162.18 C10H10O2
37 Methylether 46.07 C2H6O
38 Methylpalmitate 270.5 C17H34O2
39 Methylperillate 180.24 C11H16O2
40 Myristicacid 228.37 C14H28O2
41 Myrtenol 152.23 C10H16O
42 o-isopentenyl-halfordinol 306.4 C19H18N2O2
43 p-cymene 134.22 C10H14
44 Phytol 296.5 C20H40O
45 Piperitone 152.23 C10H16O
46 Plumbagin 188.18 C11H8O3
47 Psoralen 186.16 C11H6O3
48 Pulegone 152.23 C10H16O
49 Quercetin 302.23 C15H26O
50 Rutaretin 262.26 C14H14O5
51 Rutin 610.5 C27H30O16
52 Sabinene 136.23 C10H16
53 Sabinol 152.23 C10H16O
54 Scoparone 206.19 C11H10O4
55 Scopoletin 192.17 C10H8O4
56 Shahidine 279.3 C18H17NO2
57 Skimmianine 259.26 C14H13NO4
58 Skimmin 324.28 C15H16O8
59 Tembamide 271.31 C16H17NO3
60 Trans-carveol 152.23 C10H16O
61 Umbelliferone 162.14 C9H6O3
62 Valencicacid 206.24 C12H14O3
63 Vanillin 152.15 C8H8O3
64 Verbenone 150.22 C10H14O
65 Xanthotoxin 216.19 C12H8O4
66 α-amyrin 426.7 C30H50O
67 α-cedrene 204.35 C15H24
68 α-copaene 204.35 C15H24
69 α-cubebene 204.35 C15H24
70 α-elemene 204.35 C15H24
71 α-humulene 220.35 C15H24O
72 α-phellandrene 136.23 C10H16
73 α-pinene 136.23 C10H16
74 α-zingiberine 204.35 C15H24
75 β-amyrin 426.72 C30H50O
76 β-elemene 204.35 C15H24
78 β-eudesmol 222.37 C15H26O
79 β-funebrene 204.35 C15H24
80 β-ionone 192.3 C13H20O
81 β-myrcene 142.27 C10H16
82 β-ocimene 136.23 C10H16
83 β-phellandrene 136.23 C10H16
84 β-pinene 136.23 C10H16
85 β-selinene 204.35 C15H24
86 β-sitosterol 414.7 C29H50O
87 β-sitosterolβ-D-glucoside 576.85 C35H60O6
88 γ-sitosterol 432.7 C29H52O2
89 γ-terpinene 136.23 C10H16

Drug likeliness prediction

The drug-likeness properties of the lead molecules were assessed by submitting each molecule on Molinspiration property prediction (https://www.molinspiration.com) and SWISSADME (http://www.swissadme.ch/index.php) tools. The tool analyzes molecular properties in line with Lipinski’s rule of five, highlighting potential issues highlighted.20 Octanol/water partition coefficient (MiLogP) was computed to predict membrane permeability. It was determined by summing fragment contributions and applying correction factors, as per Molinspiration’s fragment-based method. The miLogP was derived by correlating calculated logP with experimental logP values for a set of drug-like molecules, which predicts oral bioavailability.21

Besides, the tool predicts other molecular properties (TPSA, MW, ON, OHNH, ROTB, and volume) were calculated based on the molecule’s three-dimensional conformation. Topological polar surface area (TPSA) is used to predict various aspects of drug absorption, including intestinal absorption, bioavailability, and penetration of the blood-brain barrier. TPSA is computed by summing the fragment-based contributions of polar fragments centered on oxygen and nitrogen atoms, as well as the surface areas of hydrogen-bonded oxygen and nitrogen atoms.The number of rotatable bonds (nrotb) is a topological descriptor that quantifies molecular flexibility and is a strong predictor of oral bioavailability. The volume of a molecule influences its transport characteristics, such as passage through the blood-brain barrier and intestinal absorption.22

Bioactivity Prediction

Bioactivity scores for each lead molecule were predicted based on properties such as GPCR ligand activity, ion channel modulation, kinase inhibition, and nuclear receptor binding using Molinspiration.22 

Results

Docking studies revealed that 89 phytochemicals from A. marmelos exhibit inhibitory activity against three mutated Ras proteins. The docking scores calculated using AutoDock 4.2 indicated that there are several hit molecules on each Ras protein. Hit molecules with the lowest free energy of bindingon the three mutated Ras proteins were selected as potential lead molecules. The selected leads are listed in Table 2.

Table 2: Potential Ras inhibitors identified from Aegle marmelos

Lead molecules Ras proteins ∆Gbind(kcal/mol) Inhibition constant (KI)
α-amyrin H-Ras -9.94 51.69 nM
Lupeol H-Ras -9.62 89.46 nM
Betulinic acid K-Ras -8.51 577.15 nM
β-amyrin K-Ras -8.41 684.60 nM
Lupeol K-Ras -8.40 695.44 nM
α-amyrin K-Ras -8.28 850.02 nM
β-amyrin N-Ras -9.49 110.73 nM
α-amyrin N-Ras -8.78 367.60 nM

As mentioned above, the docked results of 88 molecules on mutated H-Ras (1P2U) revealed that about 78 molecules possessed free energy of binding ≤-5 kcal/mol. Similarly, 74 molecules on K-Ras (5UFE) and 77 molecules on N-Ras (5UHV) were selected as hit molecules respectively. The selected lead molecules on each Ras protein such asα-amyrin and Lupeol on H-Ras, betulinic acid, β-amyrin and lupeol on K-Ras, β-amyrin and α-amyrin on N-Ras were depicted in Fig. 2. The molecule α-amyrin was selected as lead molecule on mutated H-Ras and N-R as according to the lead selection criteria. For mutated K-Ras, it showed only a negligible difference with the lead molecules selected. Therefore, α-amyrin can be considered as the lead molecule for mutated Ras proteins.

Figure 2: Docking conformations of lead compounds with mutated Ras proteins, a)H-Ras and α-amyrin, b) H-Ras and Lupeol, c) K-Ras and Betulinic acid, d) K-Ras and β-amyrin) K-Ras and Lupeol, f)K-Ras and α-amyrin, g) N-Ras and β-amyrin, h) N-Ras and α–amyrin

 

Click here to view Figure

The binding interactions between the docked ligand and protein are as follows (Fig.3, Table3). H-Ras and α-amyrin formed a single hydrogen bond (VAL29:H64) with a bond length of 2.13 Å and O..H-O bond type. H-Ras and lupeol interacted through a single hydrogen bond (ASP119:H75) with a distance of 2.01Å and O..H-O bond type. Likewise, single H-bonds were observed between K-Ras and β-amyrin (GLN61:H63, 2.09Å, O..H-O) and between K-Ras and lupeol (GLU31:HN1, 2.07Å, N-H..O). K-Ras and α-amyrin interacted through a single hydrogen bond (ASP30:H64) with a distance of 2.194 Å and O..H-O bond type. Betulinic acid formed two H-bonds with K-Ras, specifically at GLY13:HN (1.8 Å) and LYS16:HZ1 (1.77 Å), both of N-H..O type.N-Ras interacted with β-amyrin through one H-bond (THR35:H63, 2.03 Å, O..H-O), but no interactions were seen with α-amyrin. The analysis revealed that the lead molecules generally formed robust H-bonds with Ras proteins, with bond lengths ranging from 1.7Å to 2.2Å and N-H..O and O-H..O bond types.

Figure 3: Molecular interaction of mutated Ras proteins and lead molecules, a) H-Ras and α-amyrin, b) H-Ras and Lupeol, c) K-Ras and Betulinic acid, d) K-Ras and β-amyrin e) K-Ras and Lupeol, f) K-Ras and α-amyrin g) N-Ras and β-amyrin, h) N-Ras and α –amyrin.

 

Click here to view Figure

Table 3 : Molecular interaction between lead molecules and mutated Ras proteins

Lead

 

molecules

RAS

 

proteins

 

H-bond

Bond

 

Type

Bond

 

length

Energy

 

(kcal/mol)

 

Phi(Å)

 

Theta(Å)

α-amyrin H-Ras VAL29:H64 O..H-O 2.13 -2.27 129.66 177.48
Lupeol H-Ras ASP119:H75 O..H-O 2.01 -1.31 121.43 143.66
Betulinicacid K-Ras GLY13:HN 

LYS16:HZ1

N-H..O 

N-H..O

1.8 

1.77

-7.379 

0.674

174.3 

138.82

168.56 

122.76

ß-amyrin K-Ras GLN61:H63 O..H-O 2.09 -0.28 138.79 120.13
Lupeol K-Ras GLU31:HN1 N-H..O 2.07 -4.47 93.21 157.53
ß-amyrene N-Ras THR35:H631 O..H-O 2.03 1.4 130.17 136.78
α-amyrin N-Ras No H-bonds

Molinspiration property prediction tool and SWISSADME was used to evaluate the drug-likeness of the lead molecules (Table 4).

Table 4: Drug likeness properties predicted by Molinspiration and SWISSADME tools

Drug likeness properties α-amyrin Betulinic acid lupeol β-amyrin
MiLogP 8.08 7.04 8.29 8.02
TPSA 20.23 57.53 20.23 20.23
Number of atoms 31 33 31 31
Molecular weight 426.7 456.7 426.7 421.73
H-bond acceptor 1 3 1 1
H-bond donor 1 2 1 1
Number of violations 1 1 1 1
Number of rotational bonds 0 2 1 1
Volume 461.05 472.04 461.6 460.7
Bioavailability 0.55 0.85 0.55 0.55
Water solubility Low solubility Low solubility Low solubility Low solubility
Synthetic accessibility 6.17 6.04 5.49 6.17

The bioactivity profiles of the lead molecules were predicted using Molinspiration, covering GPCR ligands, ion channel modulators, kinase inhibitors, nuclear receptor ligands, protease inhibitors, and enzymes shown in Table 5. The bioavailability radar of each lead molecule is created using SWISSADME and in which the pink zone describes appropriate physic-chemical space for oral bioavailability. In bioavailability radar (Fig. 4), LIPO represents lipophilicity (XLOGP3), SIZE indicates molecular weight, POLAR denotes polarity (topological polar surface area), INSOLU signifies water insolubility (log S scale), INSATU reflects unsaturation (sp3 hybridization), and FLEX represents flexibility (rotatable bonds).

Table 5: Predicted bioactivity scores for the lead molecules

Lead molecules GPCR

ligand

Ion channel

modulator

Kinase inhibitor Nuclear receptor

ligand

Protease inhibitor Enzyme inhibitor
α-amyrin 0.22 -0.02 -0.41 0.79 0.19 0.6
Betulinic acid 0.31 0.03 -0.5 0.93 0.14 0.55
Lupeol 0.27 0.11 -0.42 0.85 0.15 0.52
β-amyrin 0.22 -0.05 -0.31 0.67 0.11 0.56

 

Figure 4: Bioavailability radar of the lead molecules: a) α-amyrin, b) Betulinic acid, c) Lupeol, d) β-amyrin

 

Click here to view Figure

Discussion

Ras proteins are proto-oncogenes that are commonly mutated in many human cancers. Functional anomaly of Ras function ended up with the hyperproliferative developmental disorders and cancer and is correlated with a single amino acid substitution resulting from a mutation at specific codons 12, 13 or 61. In colon cancer (adenocarcinoma), lymphomas (Hodgekins lymphoma), leukemias (AML), thyroid and (anaplastic and follicular carcinoma) high frequencies of Ras mutations (>10%) are found in lung cancers, particularly large-cell and non-small-cell carcinomas.The K-Ras locus is predominantly affected by oncogenic mutations.12Although the protein products of the three Ras genes are identical, K-Ras is the more predominantly mutated Ras in cancer.14

The evolution of human civilization and the use of plant resources for healing have been closely linked, ultimately giving rise to modern medicine.23 A. marmelosis an important medicinal plant which has enormous ethnomedicinal applications and used in different traditional and folk medicines.24The plant is enriched with various classes of active chemical constituents such as alkaloids, steroids, coumarins, terpenoids, flavonoids and many other polyphenols that are responsible for the multifaceted pharmacological and biological activities.

Earlier investigations revealed that the hydroalcoholic extract of A. marmelos leaves possesses anticancer properties, inhibiting the growth of various cancer cells, such as K562, Raji, Jurkat, and MCF714. The antiproliferative and antioxidant activity assay on ethanolic extract of A. marmelosleaves in Dalton’s Lymphoma Ascites (DLA)-bearing mice demonstrated promising result.25

The previous investigations on the hydroalcoholic extract of A. marmelosleaves have shown anticancer effect in the animal model of Ehrlich ascites carcinoma, growth of leukemic K562, B-lymphoid Raji, T-lymphoid Jurkat, erythroleukemic HEL, melanoma Colo 38, and breast cancer cell lines MCF7 and MDA-MB-23114. The antiproliferative and antioxidant activity assay on ethanolic extract of A. marmelosleaves in mice bearing Dalton’s Lymphoma Ascites (DLA) demonstrated promising result.25

The potential anticancerous activity of the plant A. marmelosbestowed by the diverse phytoconstituents and analysis of these phytomolecules against mutated three Ras proteins were seldom investigated. Computer aided drug discovery is an indispensable technique to bring down the far-reaching experimentation mandatory for the unearthing of lead molecules. Hence, virtual screening through in silico molecular docking of 89 phytochemicals from A. marmelosagainst three mutated Ras proteins were carried out to determine effective lead molecules against various Ras proteins. The analysis of the overall results proclaimed that the molecule α-amyrin showed promising free energy of binding on all the three mutated Ras proteins even though betulinic acid and β-amyrin were identified as potential lead candidates on K-Ras and N-Ras respectively.

Theoretically, ideal drug-like molecules usually possess logP values between -0.4 and 5.6, molecular weights between 160-480 g/mol, molar refractivity between 40-130, and 20-70 atoms, following Lipinski’s rule of five, whereas natural compounds frequently deviate from these parameters.25 The drug likeness prediction of all the lead molecules showed violation in miLogP (>4.15) and by making derivatives or by changing slight alteration in the chemical structure through combinatorial techniques may enhance the property. Many researchers reported that aplenty of existing drugs violate theoretical prediction of drug likeness26 specifically naturalproducts.27 In light of this, more extensive study is required for the development of these lead molecules as drugs against mutated Ras proteins mediated tumors.

Conclusion

The overall results of the virtual screening of phytochemicals in A. marmelos on three mutated Ras proteins revealed that the plant has inhibitory effects on the three mutated Ras proteins. Among the 89 phytochemicals screened, most of the molecules showed moderate inhibitory activity (≤-5kcal/mol) on all the three mutated Ras proteins. In silico drug-likeness and bioactivity prediction of the lead molecules showed that they are within the range of values except miLogP. Hence, it can be concluded that by applying combinatorial chemical approach the lead molecules will enhance the violated property and ensure them as drug molecules. The identified lead molecules exhibit anti-inflammatory and antioxidant properties, which may help in reducing neuroinflammation and neurodegeneration. Alpha amyrin, betulinic acid, lupeol, and beta-amyrins are pentacyclic triterpene compounds that exhibit a range of pharmacological properties, particularly anticancer activity, making them promising candidates for drug development. A combinatorial approach and novel formulation strategies, such as nanoemulsionscan improve the lead molecule’s bioavailability and efficacy. Moreover, pharmacological validation of these lead molecules in a relevant biological system is mandatory for the development as drug molecules. Hence, further preclinical in vitro and in vivo evaluations are essential for the development of the lead molecules as drugs against the mutated Ras proteins.

Acknowledgment

We thank the Principal, Assumption College Autonomous, Changanassery, Kerala for providing the facilities and encouragement.

Conflict of Interest

The authors declare no conflict of interest, financial or otherwise.

Funding Sources

The authors received no financial support for the research, authorship and/or publication of this article.

Data Availability Statement

This statement does not apply to this article.

Ethics statement

This research did not involve human participants, animal subjects, or any material that requires ethical approval.

Informed Consent Statement

This study did not involve human participants, and therefore, informed consent was not required.

Clinical Trial Registration

This research does not involve any clinical trials.

Permission to reproduce material from other sources

Not Applicable

Author Contribution

Nisha Nisha Bhavan Chandran: Conceptualization, Methodology, Writing- Original Draft.

Rogimon Plammoottil Thomas: Supervision, Writing- Review& Editing.

References

  1. Tariq A., Majeed I, Khurshid A. Types of Cancers Prevailing in Pakistan and their Management Evaluation. Asian Pac J Cancer Prev. 2015;16:3605-16.doi: 10.7314/apjcp.2015.16.9.3605.
    CrossRef
  2. Iqbal J, Abbasi B A, Mahmood T, et al. Plant-derived anticancer agents: A green anticancer approach. Asian Pac J Trop Biomed. 2017;7:1129-50.https://doi.org/10.1016/j.apjtb.2017.10.016.
    CrossRef
  3. Sever R, Brugge J S. Signal transduction in cancer. Cold Spring Harb Perspect Med. 2015;5(4):a006098.doi: 10.1101/cshperspect.a006098.
    CrossRef
  4. Hassanpour S H, Dehghani M. Review of cancer from perspective of molecular. J Cancer Res Pract. 2017;4:127-9.https://doi.org/10.1016/j.jcrpr.2017.07.001.
    CrossRef
  5. Santos E, Nebreda A R. Structural and functional properties of Ras proteins. FASEB J. 1989;5:2151-63.doi: 10.1096/fasebj.3.10.2666231.
    CrossRef
  6. Tripathi B K., Hirsh N H, Qian X, et al. The pro-oncogenic noncanonical activity of a RAS•GTP:RanGAP1 complex facilitates nuclear protein export. Nat Cancer. 2024;5:1902-18.https://doi.org/10.1038/s43018-024-00847-5.
    CrossRef
  7. Simanshu D K, Nissley D V, McCormick F. Ras Proteins and Their Regulators in Human Disease. Cell. 2017;170:17-33.doi: 10.1016/j.cell.2017.06.009.
    CrossRef
  8. Pierotti M A, Sozzi G., Croce C M. Mechanisms of oncogene activation. In: Kufe DW, Pollock RE, Weichselbaum RR, et al., editors. Holland-Frei Cancer Medicine. 6th ed. Hamilton (ON): BC Decker; 2003.
  9. Medarde A F, Santos E. Ras in Cancer and Developmental Diseases. Genes Cancer. 2011;2:344-58.doi: 10.1177/1947601911411084.
    CrossRef
  10. Yang X, Wu H. RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms. J Hematol Oncol. 2024;17(1):108.doi: 10.1186/s13045-024-01631-9.
    CrossRef
  11. Hood F E, Sahraoui Y M, Jenkins R E, Prior I A. Ras protein abundance correlates with Ras isoform mutation patterns in cancer. Oncogene. 2023;42:1224-32.doi: 10.1038/s41388-023-02638-1.
    CrossRef
  12. Khan T, Ali M, Khan A, Nisar P, Jan SA, Afridi S, Shinwari ZK. Anticancer Plants: A Review of the Active Phytochemicals, Applications in Animal Models, and Regulatory Aspects. Biomol. 2019; 27;10(1):47. doi: 10.3390/biom10010047.
    CrossRef
  13. Rahman S, Parvin R. Therapeutic Potential of Aegle marmelos (L.)-An overview. Asian Pac J Trop Dis. 2014;4:71-7.doi: 10.1016/S2222-1808(14)60318-2.
    CrossRef
  14. Baliga M S, Thilakchand K R, Rai M P, Rao S, Venkatesh P. Aegle marmelos (L.) Correa (Bael) and its Phytochemicals in the Treatment and Prevention of Cancer. Integr Cancer Ther. 2013;12:187-96.doi: 10.1177/1534735412451320.
    CrossRef
  15. Guex N, Peitsch M C. SWISS-MODEL and the Swiss-PdbViewer: an environment for protein modelling. Electrophoresis. 1997;18:2714-23.doi: 10.1002/elps.1150181505.
    CrossRef
  16. Nisha N C, Sreekumar S, Evans D A, Biju C K. In vitro and in silico validation of anti-cobra venom activity and identification of lead molecules in Aegle marmelos (L.) Correa. Curr Sci. 2018;114(6):1214-9.doi:10.18520/cs/v114/i06/1214-1221.
    CrossRef
  17. Morris G. M, Huey R, Lindstrom W, et al. AutoDock4and AutoDock Tools4: Automated docking with selective receptor flexibility. J Comput Chem. 2009;30:2785-91.doi: 10.1002/jcc.21256.
    CrossRef
  18. The PyMOL Molecular Graphics System, Version 1.2r3pre, Schrödinger, LLC.
  19. Lipinski C A, Lombardo F, Dominy B W, Feeney P J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46(1-3):3-26.doi: 10.1016/s0169-409x(00)00129-0.
    CrossRef
  20. Nisha N C, Sreekumar S, Biju C K, Krishnan P N. Identification of lead compounds with cobra venom neutralizing activity in three Indian medicinal plants. Int J Pharm Pharm Sci. 2014;6(2):536-41.
  21. Wardecki D, Dołowy M, Bober-Majnusz K. Assessment of Lipophilicity Parameters of Antimicrobial and Immunosuppressive Compounds. Molecules. 2023;28(6):2820.https://doi.org/10.3390/molecules28062820.
    CrossRef
  22. Nisha N C, Sreekumar S, Biju C K. Identification of lead compounds with cobra venom detoxification activity in Andrographis paniculata (Burm. F.) Nees through in silico method. Int J Pharm Pharm Sci. 2016;8(7):212-7.
  23. Petrovska B B. Historical review of medicinal plants’ usage. Pharmacogn Rev. 2012;6(11):1-5.doi: 10.4103/0973-7847.95849.
    CrossRef
  24. Vaza J S, Bhalerao SA. Bael (Aegle marmelos L.) as a potential medicinal tree: an overview. World J Pharm Sci. 2018;7(11):1406-14.
  25. Chockalingam V, Kadali S S, Gnanasambantham P. Antiproliferative and antioxidant activity of Aegle marmelos (Linn.) leaves in Dalton’s Lymphoma Ascites transplanted mice. Indian J Pharmacol. 2012;44(2):225-9.doi: 10.4103/0253-7613.93854.
    CrossRef
  26. Kadam R U, Roy N. Recent trends in drug-likeness prediction: A comprehensive review of in silico methods. Indian J Pharm Sci. 2007;69(5):609-15.
    CrossRef
  27. Ganesan A. The impact of natural products upon modern drug discovery. Curr Opin Chem Biol. 2008;12(3):306-7.doi: 10.1016/j.cbpa.2008.03.016.
    CrossRef

Abbreviations list

∆Gbind– free energy of binding

DNA – Deoxy ribo nucleic acid

kcal/mol – Kilo calories per molecule

H-RAS – Harvey rat sarcoma viral oncogene

N-RAS – Neuroblastoma rat sarcoma viral oncogene

K-RAS – Kirsten rat sarcoma viral oncogene

etc– Et cetera

A. marmelosAegle marmelos

L. – Linnaeus

viz. – videlicet/namely

RCSB –Research Collaboratory for Structural Bioinformatics

g/mol – gram per mol

et al. –  etaliae/ and others

Fig. – Figure

SMILES – Simplified Molecular Input Line Entry Systems

nrotb – number of rotatable bonds

miLogP– Molinspiration Logarithm of the Partition Coefficient

logP – logarithms of the Octanol-Water Partition Coefficient

TPSA- Total Polar Surface Area

MW – Molecular weight

ON – Hydrogen bond acceptors / Oxygen and Nitrogen atoms

OHNH – Hydrogen bond donors / Hydroxyl and amine groups

ROTB – Rotatable bonds

TPSA – Topological Polar Surface Area

Article Publishing History
Received on: 14-12-2025
Accepted on: 21-01-2026

Article Review Details
Reviewed by: Dr. Omar Kiydar Hassan
Second Review by: Dr. Ankur Vashi
Final Approval by: Dr. Wagih Ghannam


Share

FOLLOW US ON:

facebook Twitter Mendeley LinkedIn

SEARCH WEBSITE

MEMBER OF

Logo-image

JOURNAL ARCHIVED IN

Logo-image